KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and Safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center Phase III Trial.

Sun Young Choi, Beom Joon Kim, Yang Won Lee, Won-Serk Kim, Yi Na Yoon, Jin Seop Kim

J Cosmet Dermatol 24(7) e70305

PMID40586136
PMCIDPMC12207567
DOI10.1111/jocd.70305
发表日期2025-06-30
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:森林图/亚组分析图。
摘要

摘要

BACKGROUND: Botulinum toxin is a key treatment for dynamic wrinkles. OBJECTIVE: This study evaluates CKDB-501A, a botulinum toxin completely free from animal-derived components including human-serum albumin, comparing its efficacy and safety to onabotulinumtoxinA (ONA) for the treatment of moderate-to-severe glabellar lines. METHODS: In this phase 3 trial, 300 subjects with moderate-to-severe glabellar lines were randomized to receive CKDB-501A or ONA. The primary efficacy endpoint was the investigator-assessed improvement rate for frowning at week 4, defined as a ≥ 2-point improvement from baseline on the 4-point Facial Wrinkle Scale (FWS). Secondary efficacy endpoints included photo-assessed improvement rates and subjects' overall assessment and satisfaction. Safety was evaluated by the monitoring of adverse events (AEs) and neutralizing antibodies formation. RESULTS: At week 4, 80.69% of the CKDB-501A group achieved a ≥ 2-point improvement in FWS score versus 70.83% for ONA, confirming non-inferiority (95% CI: 0.09-19.55, p = 0.0491). Secondary endpoints showed no significant differences between groups, with sustained efficacy up to 16 weeks. Approximately 70% maintained at least a 1-point improvement. Photo-assessed and subjects' overall improvement and satisfaction rates were consistent with primary findings. Both treatments had comparable safety profiles, with no AEs related to the local and distant spread of toxin, hypersensitivity reactions, or neutralizing antibodies formation. CONCLUSION: CKDB-501A is a safe and effective alternative to existing botulinum toxin products for treating moderate-to-severe glabellar lines, offering benefits of improved biocompatibility and reduced risk of allergic reactions. CLINICALTRIALS: gov: NCT05804656.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Subject disposition.
非 KM Figure
FIGURE 2FIGURE 2 Primary efficacy results (a) investigator‐assessed ≥ 2‐point improvement rates. (b) Photographs of female (upper) and male (lower) subjects treated with CKDB‐501A achieving ≥ 2‐point improvement. The primary efficacy endpoint was defined as the subject achieving at least a 2‐point improvement from baseline in the investigator‐assessed FWS score at maximum frown. Photographs of subjects treated with CKDB‐501A who achieved a ≥ 2‐point improvement are shown in (b). Left photographs show the baseline condition, and right photographs show the condition at week 4. Subjects fully consented to the use of their photographs for publication purposes. Statistical analysis was conducted on the per‐protocol set using the Cochran–Mantel–Haenszel test, adjusting for study site. An asterisk (*) indicates a significant difference at p < 0.05. ONA, onabotulinumtoxinA.
非 KM Figure
FIGURE 3FIGURE 3 Investigator‐assessed ≥ 1‐point improvement rates (a) at maximum frown (b) at rest. Statistical analysis was conducted on the per‐protocol set using the Cochran–Mantel–Haenszel test, adjusting for study site. When analyzing ≥ 1‐point improvement at rest, subjects with a baseline rest score of 0 were excluded. ONA, onabotulinumtoxinA.
非 KM Figure
FIGURE 4FIGURE 4 Post hoc analysis results (a) proportion of subjects achieving an investigator‐assessed FWS score of 0 (none) at maximum frown at week 4, (b) forest plot for investigator‐assessed ≥ 2‐point improvement rate at maximum frown at week 4 by baseline severity, age group, and gender. Statistical analysis was conducted on the per‐protocol set using the chi‐squared test (C) or Fisher's exact test (F). A vertical dotted line indicates a non‐inferiority margin of −15%. CI, confidence interval; ONA, onabotulinumtoxinA.
非 KM Figure